Drugs / Otamixaban
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01126086 | May 2010 → Apr 2011 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01120314 | Apr 2010 → Jul 2011 | impaired renal function disease | Sanofi | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT00317395 | Jun 2006 → Oct 2008 | coronary artery disorder | Sanofi | Completed | Missed primary |
| Phase 2 | NCT00133731 | Sep 2004 → Oct 2005 | — | Sanofi | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01076764 | Apr 2010 → May 2013 | acute coronary syndrome | Sanofi | Completed | Missed primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Otamixaban | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00133731 ↗ |
| Known as | FXV-673 | ChEMBL registry synonym — accepted as the source's own label CHEMBL46618 ↗ |
| Known as | RPR-130673 | ChEMBL registry synonym — accepted as the source's own label CHEMBL46618 ↗ |
| Known as | XRP0673 | “Otamixaban (XRP0673)” NCT00133731 ↗ |
| Action | Inhibit | “Factor Xa Inhibitor Otamixaban” NCT00133731 ↗1“Coagulation factor X inhibitor” CHEMBL46618 ↗ |
| Modality | Small molecule | — CHEMBL46618 ↗ |
| Route | Intravenous | “intravenous regimens of Factor Xa Inhibitor Otamixaban” NCT00133731 ↗ |
| Target | F10 | “Coagulation factor X inhibitor” CHEMBL46618 ↗ |